The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.

RUSSO, A., FRATTO, M.E., BAZAN, V., SCHIR, V., AGNESE, V., CICERO, G., et al. (2007). Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. EXPERT OPINION ON THERAPEUTIC TARGETS, 11(12), 1571-1586 [10.1517/14728222.11.12.1571].

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.

RUSSO, Antonio;BAZAN, Viviana;AGNESE, Valentina;CICERO, Giuseppe;
2007-01-01

Abstract

The ubiquitin-proteasome pathway is the main proteolytic system present in the nucleus and cytoplasm of all eukaryotic cells. Apoptosis activation induced by ubiquitin-proteasome pathway inhibition makes the proteasome a new target of anticancer therapy. Bortezomib is the first proteasome inhibitor to be approved by the US FDA; in 2003 as a third line and in 2005 as a second line therapy for the treatment of multiple myeloma only. This review focuses on the use of bortezomib, not only in its therapeutic role but also, more specifically, in its biologic role and discusses the most recent applications of the drug in solid tumors, both at a preclinical and clinical level.
2007
Settore MED/06 - Oncologia Medica
RUSSO, A., FRATTO, M.E., BAZAN, V., SCHIR, V., AGNESE, V., CICERO, G., et al. (2007). Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence. EXPERT OPINION ON THERAPEUTIC TARGETS, 11(12), 1571-1586 [10.1517/14728222.11.12.1571].
File in questo prodotto:
File Dimensione Formato  
Russo Expert Opinion 2007.pdf

Solo gestori archvio

Dimensione 272.35 kB
Formato Adobe PDF
272.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/27326
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 16
social impact